Clinical Trial: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07518186) titled 'A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma' on April 01.

Brief Summary: The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Study Start Date: June 09

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma

Intervention: DRUG: JNJ-79635322

JNJ-79635322 will be administered as SC injection.

DRUG: Teclistamab

Teclistamab will be administered as SC injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Janssen Research & Development, LLC

Published by HT Digital Content Services with permission from Health Dail...